Form S-3 | Jotup

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Retrieved on:

Thursday, March 28, 2024

Floor, Needham & Company, Madison Avenue, Central nervous system, Form, Telephone, CNS, Truist, Sale, Attention, Security (finance), Guggenheim Partners, Form S-3, Praxis, Nicollet Mall

The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.

Key Points:

The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.
All shares and pre-funded warrants in the offering are being offered by Praxis.
In addition, Praxis has granted the underwriters a 30-day option to purchase up to 530,973 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about April 2, 2024, subject to market conditions and the satisfaction of customary closing conditions.

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Retrieved on:

Wednesday, March 27, 2024

Floor, Needham & Company, Madison Avenue, Central nervous system, Form, Telephone, CNS, Truist, Sale, Attention, Security (finance), Guggenheim Partners, Form S-3, Praxis, Nicollet Mall

All securities in the offering will be offered by Praxis.

Key Points:

All securities in the offering will be offered by Praxis.
Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering.
The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed.
The proposed offering will be made only by means of a preliminary prospectus supplement and the accompanying base prospectus.

Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

Retrieved on:

Wednesday, March 27, 2024

Common stock, Private, Exercise, Form, Telephone, Common, Sale, Attention, Prospectus, Form S-3, P.C, Security (finance)

In a concurrent private placement, the Company also agreed to sell to the same investors, common warrants (“Common Warrants”).

Key Points:

In a concurrent private placement, the Company also agreed to sell to the same investors, common warrants (“Common Warrants”).
Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.76 million, the maximum availability under the effective shelf registration statement.
The Common Warrants are exercisable immediately subject to registration and expire 5 years after the initial issuance date.
The registered direct offering is being made pursuant to an effective shelf registration statement on Form S-3 (No.

INNOVATE Corp. Announces Extension of Rights Offering Subscription Period

Retrieved on:

Monday, March 25, 2024

Form, Prospectus, Form S-3, Sale, Panzer corps

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE), a diversified holding company, announced today that its Board of Directors has extended the subscription period for its rights offering to 5:00 p.m. Eastern Time on April 9, 2024, in order to allow stockholders and noteholders who are entitled to participate in the rights offering (holders of record of the Company’s common stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and 2026 Convertible Notes as of 5:00 p.m. Eastern Time on March 6, 2024) additional time to participate.

Key Points:

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE), a diversified holding company, announced today that its Board of Directors has extended the subscription period for its rights offering to 5:00 p.m. Eastern Time on April 9, 2024, in order to allow stockholders and noteholders who are entitled to participate in the rights offering (holders of record of the Company’s common stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and 2026 Convertible Notes as of 5:00 p.m. Eastern Time on March 6, 2024) additional time to participate.
The rights offering is being made pursuant to INNOVATE’s effective shelf registration statement on Form S-3, filed with the SEC on September 29, 2023 and declared effective on October 6, 2023, and a prospectus supplement containing the detailed terms of the rights offering filed with the SEC on March 8, 2024.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities (including without limitation the preferred stock issued and sold in the concurrent private placement), nor shall there be any offer, solicitation or sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful under the securities laws of such state or jurisdiction.
The rights offering was made only by means of a prospectus and a related prospectus supplement, copies of which were distributed to all eligible rights holders as of the rights offering record date and may also be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting the information agent for the rights offering.

SINTX Technologies Announces Proposed Public Offering of Common Stock

Retrieved on:

Friday, March 22, 2024

Form, Telephone, Sale, Attention, Prospectus, Form S-3

SALT LAKE CITY, UT, March 22, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today announced that it intends to offer and sell shares of its common stock in a public offering.

Key Points:

SALT LAKE CITY, UT, March 22, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today announced that it intends to offer and sell shares of its common stock in a public offering.
All shares of common stock in the offering are to be offered by SINTX.
SINTX intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes.
Maxim Group LLC is acting as sole placement agent, on a reasonable best efforts basis, for the proposed offering.

Workhorse Strengthens Financial Position with Convertible Note Transaction

Retrieved on:

Tuesday, March 19, 2024

Form, Sale, Security (finance), Prospectus, Form S-3, Draft horse

In connection with the agreement, the Company completed a registered direct offering pursuant to which it issued and sold to the Investor a $9 million note and related warrants (the “March Securities”).

Key Points:

In connection with the agreement, the Company completed a registered direct offering pursuant to which it issued and sold to the Investor a $9 million note and related warrants (the “March Securities”).
The sale of the March Securities provides Workhorse immediate liquidity which is being used to fund operations and redeem the remaining $2,500,000 in aggregate principal amount of its existing Green Senior Secured Convertible Note.
The March Securities were offered in the registered direct offering pursuant to a registration statement on Form S-3 (File No.
333-273357), which was declared effective by the Securities and Exchange Commission (the “SEC”) on July 28, 2023.

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement

Retrieved on:

Friday, April 5, 2024

Subject to Biodesix stockholder approval, each share of Series A Non-Voting Convertible Preferred Stock will automatically convert to 40 shares of common stock for an aggregate of 30,434,280 shares of common stock.

Key Points:

Subject to Biodesix stockholder approval, each share of Series A Non-Voting Convertible Preferred Stock will automatically convert to 40 shares of common stock for an aggregate of 30,434,280 shares of common stock.
The gross proceeds to Biodesix from the underwritten offering and concurrent private placement, before deducting underwriting discounts and commissions, placement agent fees and other offering expenses payable by Biodesix, and following the receipt of stockholder approval, are expected to be $55.0 million.
TD Cowen, William Blair and Canaccord Genuity are acting as joint bookrunning managers for the underwritten offering and placement agents for the concurrent private placement.
Lake Street Capital Markets is acting as lead manager for the underwritten offering and placement agent for the concurrent private placement.

Pulse Biosciences Announces Plans to Initiate a Rights Offering

Retrieved on:

Thursday, March 28, 2024

Biotechnology, Medical Devices, Health, Health Technology, Cardiology, Common stock, Exercise, Date, Form, Sale, Security (finance), Prospectus, Form S-3

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering.

Key Points:

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering.
The rights offering will include an over-subscription right to permit each rights holder that exercises its basic subscription rights in full to purchase additional Units that remain unsubscribed at the expiration of the offering.
Robert Duggan, the Company’s Executive Chairman and majority stockholder, has indicated his support for the rights offering and his intent to participate in the rights offering on the same terms as all other investors.
The rights offering will be made pursuant to a registration statement on Form S-3 containing the detailed terms of the rights offering to be filed with the SEC.

Sky Harbour Group Corporation Announces its 2023 Financial Results; Updates on New Ground Leases, Construction and Hangar Leasing; Injects Equity into Obligated Group and Files Various Registration Statements with SEC

Retrieved on:

Wednesday, March 27, 2024

New ground lease at SJC, encompassing an existing hangar facility to be made operational over the coming several weeks, and land for additional future development.

Key Points:

New ground lease at SJC, encompassing an existing hangar facility to be made operational over the coming several weeks, and land for additional future development.
New ground lease at ORL, with expected construction commencement in Q2 2025.
Construction of Phases 1 in Denver, Phoenix, and Dallas delayed by 3-4 months, with an estimated $26 - $28 million non-recurring remediation cost.
We are now gearing up to perform at scale.”
Sky Harbour will host a live conference call and concurrent webcast at 5 p.m.

Stoke Therapeutics Announces Proposed Public Offering

Retrieved on:

Tuesday, March 26, 2024

Health, Genetics, General Health, Pharmaceutical, Optical, Biotechnology, Form, Telephone, Research, Sale, Public expenditure, Security (finance), Prospectus, Form S-3, Broadridge Financial Solutions, Therapy, J.P. Morgan & Co.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock.

Key Points:

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock.
In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
All of the shares of common stock are being offered by Stoke.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.